RxDoctor Payments Data

Kathryn Gahagan

Optometrist · Lockport, NYNPI 1124431739

Payments from drug & device makers

$2,143in general payments, 2019–2025

Across 86 payments — averaging $24.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$396
  • Alcon$388
  • Sun Pharmaceutical Industries Inc.$366
  • Oyster Point Pharma, Inc.$219
  • Bausch & Lomb Americas Inc.$195
  • Sight Sciences, Inc.$152
  • plus $427 from 8 others

What the payments were for

  • Food & beverage$2,143100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,143 in reported general payments places this provider in the 75th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$45,804
Medicare patients
305
Services billed
504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast28$41,033
RestasisCyclosporine28$36,161
Cyclosporine47$32,974
CequaCyclosporine13$20,615
LumiganBimatoprost32$20,301
Brimonidine Tartrate33$5,020
Latanoprost164$3,177
SimbrinzaBrinzolamide/Brimonidine Tart14$2,851
Prednisolone Acetate34$1,160
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat22$721
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha44$697
Dorzolamide Hcl19$355
ErythromycinErythromycin Base23$336
Ofloxacin17$239
Timolol Maleate14$236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$396$56,46160 claims
Bausch & Lomb Americas Inc.Xiidra$195$41,03328 claims
Sun Pharmaceutical Industries Inc.Cequa$366$20,61513 claims
AlconSimbrinza$388$2,85114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,743 optometrist providers in New York.

Other optometrist in Lockport

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →